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Identification of Synonymous Genes and Pathways
Implicated in Irritable Bowel Disease and
Pancreatic Duct Adenocarcinoma
Lavanya Uppala

Abstract—Better understanding and genetic characterization
of the gut microbiome will allow for the identification of clinically
distinct gastrointestinal diseases. Facilitated by high throughput
technologies, intestinal flora analyses have elucidated a broad
spectrum of neuropsychiatric, immunological, and allergic disorders linked with this organ system. Microbiome research especially has shed light on underlying factors of intestinal disorders.
This interplay of environmental bacteria versus host tissue gene
expression may have implications for disease pathogenicity and
etiological determination. For instance, pancreatic disorders are
common symptoms of irritable bowel disease (IBD), which is
thought to affect approximately 7% to 21% of the population
[1]. However, IBD is often difficult to diagnose and treat as it
presents with a constellation of symptoms, many of which are
similar to other common gastrointestinal diseases. Thus, clinical
diagnosis of IBD is typically only made when biomarkers for
other common gastrointestinal diseases are absent. Similarly,
pancreatic ductal adenocarcinoma (PDAC) accounts for over 90%
of known malignancies of the pancreas [2]. PDAC also presents
with a similar clinical prodrome to other common gastrointestinal
illnesses, leading to late diagnosis. These potentially pleiotropic
genes involved in such diseases can be identified as biomarkers
through gene expression analyses to use in the form of a
diagnostic tool. Such a mechanism may inform clinical decisionmaking, in turn leading to better patient outcomes.
Index Terms—irritable bowel disorder (IBD), irritable bowel
syndrome (IBS), pancreatic duct adenocarcinoma (PDAC), gastrointestinal illness, gut microbiome, host tissue expression, gene
expression, pathway analysis.

I. I NTRODUCTION

T

HE gastrointestinal system is a complex amalgamation
of organs that helps an individual digest food, process
nutrients, and regulate various hormone levels in the body.
Due to its function, this organ system is subject to influence
from both the environment and intrinsic physiological factors
of the patient. Current research identifies that the biggest of
these factors are the gut microbiome and more recently the
immune system which may cause the symptom of chronic
inflammation, a often seen prodrome, or early clinical marker,
of various gastrointestinal illnesses [3].
However, this interplay between the host and the gut microbiome complicates medical diagnoses, and makes it difficult to
identify clinical biomarkers of disease with their presentations.
For instance, irritable bowel disease (IBD), also known as
irritable bowel syndrome (IBS), is marked by symptoms
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including cramping, abdominal pain, bloating, gas, diarrhea,
or constipation which are akin to many other common gastrointestinal disorders as severe as celiac disease, pancreatitis,
ulcers, Crohn’s disease, or as simple as the common stomach
ache or appendicitis, and more [1]. In turn, individuals who
have some food sensitivities or have a modicum of intestinal
dysbiosis due to uncontrollable factors, present with similar
symptoms [4]. This, IBD’s constellation of symptoms and
similarities to other common gastrointestinal illnesses, is what
makes it difficult to diagnose and treat, with professional
diagnosis often being difficult to achieve and undertreatment
being rampant.
Historically, there have been many different approaches to
the diagnosis of gastrointestinal disorders, including blood
tests, endoscopies, colonoscopies, stool tests, barium swallowing radiography, CT or MRI scans, sonograms, biopsies, and
many more [5]. However, such methods typically must be used
in conjunction with each other, which may pose an unnecessarily invasive and expensive burden on the patient. Instead,
using gene expression profile and pathway analysis of tissue
samples from routine clinical procedures or from stool samples
may provide an more easily obtainable research specimen and
are often more insightful regarding the diseases’ genetic and
symptomatic heterogeneity. That is, gene expression panels,
as diagnostic tools, have proven utility in the clinical sphere.
One such panel was published by Plevy et al [6]. This
group found that the A4-Fla2 and FlaX serological markers
differentiated non-IBD, Crohn’s disease, and ulcerative colitis
(UC) patients with 87% accuracy (95% CI, p-value<0.001),
while Crohn’s vs. UC differentiation was as high as 93%
(95% CI, p-value<0.001) [6]. More specifically, signaling of
specific genes, such as IFN-γ in Helicobacter pylori infections,
have been shown to differentially exacerbate disease severity
[6], [7]. Thus, better characterization of the gene expression
profiles of common gastrointestinal diseases serves the dual
purpose of creating a pseudo-standardized scale of disease
severity on which patients can be rated, as well as preventing
potentially costly overtreatment [8].
Many gastrointestinal disorders also have root in the dysfunction of the gut microbiome, which impacts or regulates
such disease pathways. Yet, given the incredible diversity
and abundance of microbes on the planet; especially those
that are implicated in human health, it is nearly impossible
to connect physiological states with microbial community
composition [9]. This effect is further confounded when one
considers the fact that environmental factors, such as diet,
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stress, exercise, medication use, are also significant regulators
of the gut microbiome along with more intrinsic factors
such as genetics and immune systems. Moreover, as the
gut microbiome undergoes periods of growth and variation,
gastrointestinal disorders vary in their severity, at times even
having periods of remission without the necessity of medical
intervention [10]. A study by Halfvarson et al. even found that
the microbiomes of patients with IBD fluctuated more than
those of healthy patients [11]. Further supporting this theory,
Morgan et al. found that although microbial composition was
altered in disease sample data sets compared to controls,
microbial function was more often altered, with major changes
occurring with nutrient transport and uptake [12]. Accordingly,
this provides initial evidence that altered gut microbiome
conditions, and thus altered bacterial mechanistic functions
and pathways, have large scale involvement in gastrointestinal
disease pathogenesis.
However, many studies have also intimated that there is
an interplay between immunological response to food-borne
stimuli involved in disorders under the IBD umbrella. In other
words, some groups believe that IBD-related illnesses may
simply be an immune reaction to diet or environment. While
this juxtaposition of causes, between the gut microbiome and
the immune system, is well known for this group of illnesses,
it is not well characterized. As aforementioned, due to the
environmental and symptomatic variation of patients with
gastrointestinal disease, cross-sectional studies are difficult
to design, likely contributing to the lack of data regarding
these interactions. However, bioinformatics methodologies are
beginning to allow for solutions to these difficulties with
the ability to integrate “big data”, which can account for
widespread public health concerns. More specifically, RNA
sequencing analyses show great utility in this realm. RNA,
or more specifically tRNA, are core components of all living
cells and can be used to identify the taxonomic grouping of
different organisms [9]. RNA also supports the downstream
proteomic or multi-omic analyses which can help identify
functional elements within an analysis [13]. Such methodologies of RNA-sequencing based gene expression profiles
have even helped some labs identify molecular subtypes and
biomarkers of colorectal cancer [14], [15], one of the most
common types of cancer in the world [16]. In other words,
RNA provides transcriptomic understanding of intestinal and
immune system illnesses, due to their ability to characterize
organism composition as well as functional relationships.
Other studies have shown how gene expression analyses
may also provide insight into environmental factors [17],
and the role of the gut microbiota in the development of
immune responses [18]. Many groups, like Siegel et al.
and Tarallo et al., have found that altered gene expression
profiles in gastrointestinal illnesses can also be correlated
with transcriptomic changes in the gut microbiome [10], [16]–
[18]. These examples show that metatranscriptomic analyses
of the gut microbiome can elucidate differences between
common gastrointestinal diseases. With better knowledge of
environmental and immunological factors implicated in such
clinically indistinct diseases, identification of genetic components contributing to such an illness’s etiology becomes easier.
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Identifying and utilizing these biomarkers for the creation of
diagnostic tools can better inform treatment of this umbrella
of illnesses, in turn leading to better clinical outcomes for
patients [19].
Accordingly, the research directive focuses on how gene
expression profiling and pathway analysis of these illnesses
(IBD and PDAC) can identify unique pathways, genes, and
proteins implicated in each disorder. Due to the varied nature
of IBD and PDAC, identifying the genetic intersection of
tissue and microbiome gene expression will reveal genes
which are confirmed to be involved in the illnesses with
a low false discovery rate. These distinct biomarkers may
then be connected to clinical presentations of the disorders,
to better characterize and diagnose the disorder, allowing
patients to be better treated. The goal of this study is to
identify gene expression profiles and associated pathways in
common intestinal diseases. A special focus on the interplay
between immunology and environmental or gut microbiome
factors involved in IBD will be taken. Thus, identifying the
role of physiology versus lifestyle will provide insight into
treatment options, as IBD and PDAC may be underdiagnosed
and undertreated based on disease etiology or prodromic
conditions.
II. M ETHODS
A. Data Retrieval and Preprocessing
The bioinformatics workflow used for the experiment is seen
in Figure 1. First, gene expression datasets for irritable bowel
disease (IBD) and pancreatic duct adenocarcinoma (PDAC),
for both tissue cells and the microbiome of the respective
organ, were collected from the NCBI Gene Expression Omnibus (GEO) [20] database. All data was generated using
the Affymetrix Human Transcriptome Array 2.0 platform and
were from human patients. Effectively, given that the data
is coming from a variety of different sources, the data was
also be processed or cleaned to ensure that all information
is standardized. Data pre-processing, including comparisons,
were accomplished by original programs written in Python.
Currently, the main dataset that utilized for IBD was supplied by Chang and Mayer, which contains 25 IBD patients
and 21 healthy controls (GSE63379) [21]. The Chang and
Mayer dataset contains gene expression profiling of peripheral
blood mononuclear cells (PBMCs). PBMCs are known to
be implicated in selective immune system responses, as well
as being the major cells involved in immunity overall (i.e.
lymphocytes, monocytes, macrophages, etc.) [22]. Thus, given
the putative highly immunologic nature of gastrointestinal
disease, these cells act as the bridge between the physiological
and environmental aspects of IBD, and thus are a critical
host of information. Validation of these results is conducted
using the expression data from 4 healthy volunteers and 5
IBD patients dataset published by Martinez and Santos which
elucidates histopathological factors which implicate the immune system in gastrointestinal disease etiology (GSE14841)
[23]. Essentially, the Martinez and Santos dataset acts as a
measure of the IBD gut microbiome between healthy and ill
patients using the jejunum to which the Chang and Mayer
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Fig. 1. Bioinformatics workflow used to compare and analyze gene expression and pathway differences between PDAC and IBD, health and ill, patient
datasets. Functional annotation was achieved using Bioconductor goFunction package, and Kyoto Encyclopedia of Genes and Genomes (KEGG).

dataset acts as a measure of the host tissue cells. The jejunum
is the middle part of the small intestine between the duodenum
and ileum which assists in further digestion of food, as well
as the absorption of nutrients.
Similarly, Schmittigen et al. have published data of gene
expression profiling using 8 healthy and 14 PDAC tissue
samples (GSE71989) [24], while Hirahoka et al. use data
which represents the pancreas microbiome (GSE19650) [25].
The latter contains 7 healthy samples and 15 samples with
PDAC. That is, these pancreatic tissue and pancreatic microbiome datasets present the intersection of the host tissue
and gut microbiome for PDAC-affected patients. For PDAC,
the immune aspect is represented by intraductal papillarymucinous neoplasm tissue (IPMN) gene expression, while
pancreatic biome expression is taken from the tissues of the
organ itself. The benefit of using neoplastic tissues is that it
accounts for the carcinogenesis of PDACs, and the transition
from the benign papillary-mucinous adenoma variant to the
malignant carcinoma.
Volcano plots of gene expression were generated in R to
qualitatively visualize the relative numbers of significantly
differentially expressed genes for both illnesses.
B. Gene Expression Analyses
From these datasets, probes were first mapped to genes using a Python script and the Affymetrix Human Transcriptome
Array 2.0 probe set provided by the company. Differentially
expressed genes between the healthy and ill patients were
then identified using the R limma [26], affy [27], and hgu133plus2.db [28] libraries, with further filtration performed
using another novel Python script. In turn, this gene set was
again compared between the microbiome and immune system
to find genes that are confirmed to be implicated in the illness.
Identification of significantly (p<0.05) and differentially expressed genes and comparison between datasets was conducted

using a slurm script on the Holland Computing Center (HCC).
Given that the Benjamini and Hochberg adjusted p-value
yielded no significantly differentially expressed genes for the
IBD tissue sample dataset, the unaltered p-value was preferred
in this scenario. Computing was performed on the HCC due
to the large data set and subsequently great processing power
required for adequate efficiency.
C. Pathway Analysis and Functional Annotation
Using the gene expression data collected from NCBI
GEO [20], for each of the diseases, pathway analysis in
R was conducted using various Bioconductor libraries, such
as GOFunction [29], org.Hs.eg.db [30], pathview [31], and
ReactomePA [32]. This code enabled the visualization of
differentially expressed genes to their respective pathways in
the intestine and pancreas using the Kyoto Encyclopedia of
Genes and Genomes (KEGG) [33]–[35], REACTOME [36],
and gene ontologies (GO). To accomplish this, the obtained
gene symbols were first converted to Entrez ids, removing
any components which could not be mapped. These pathway
charts were then compared, and a literature review conducted
to better understand the roles of specific genes in the context
of gastrointestinal disease. A focus was placed on identifying
any correlations between pathways and clinical symptoms.
III. R ESULTS
Prior to full gene expression analyses, differential gene
expression for each illness was characterized using volcano
plots (Figures 2 and 3). However, we see here that there
are seemingly next to no significantly differentially expressed
genes when using the IBD PBMC or immune system dataset
when using the Benjamini and Hochberg adjusted p-value
(Figure 2). Accordingly, to mitigate this issue, genes that were
significantly expressed based on an unaltered p-value were
utilized. While this may slightly increase the false discovery
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rate, the overlap of the datasets is able to minimize this
through the amount of data used for analysis. That is, later
discovery shows that the overlap between datasets is fairly
minimal despite cross checking thousands of genes. This same
calculation was not an issue for the PDAC datasets, as is seen
through the volcano plots in Figures 3. Still, for maximum
possible standardization, a non-adjusted p-value was utilized.
After processing the raw data, it was discovered that the PDAC
dataset had thousands of differentially expressed genes, with
hundreds for the IBD dataset.
Overall, initial results revealed that there is much smaller
overlap between the expression of the gut microbiome and tissue samples involved in IBD versus the overlap seen between
pancreatic cells and the gene expression seen in the pancreatic
duct, despite having relatively similar numbers of expressed
genes (Table 1). Comparing the gene lists, 64 commonly
differentially expressed genes were identified between the IBD
gut microbiome and stomach cells, while 19099 commonly
differentially expressed genes were identified between the
pancreatic duct biome and pancreatic cells. There are 27 commonly differentially expressed genes between both illnesses
with duplicates and known homologs removed (Table 1).
TABLE I
D IFFERENTIALLY E XPRESSED G ENES A SSOCIATED WITH IBD AND PDAC
D ISEASE S TATES
Gene Symbol
SLC19A1
TAPBP
SQSTM1
GADD45B
CSAD
CARS2
LTBR
MED20
DAGLB
SMCR8
PNRC1
HLA-C
TMUB2
BRD7
SMG8
MTX1
MZF1
PTAFR
TTYH2
CTRL
PGLS
HK2
IL12RB1
HECTD2
NFIC
ELOVL6

IBD Microbiome logFC
0.890537
0.597237
0.591454
0.545506
0.426277
0.382721
0.379235
0.332045
0.306691
0.264237
0.261289
0.259588
-0.18629
-0.21192
-0.23621
-0.24454
-0.28754
-0.32534
-0.34464
-0.35785
-0.37849
-0.43142
-0.44687
-0.48684
-0.5669
-0.68895

PDAC Microbiome logFC
2.253729
1.378669
-0.88035
2.524668
2.132834
-0.68654
1.409514
-1.52301
0.712591
-0.56907
1.569592
-1.24977
-0.68216
0.514129
0.570852
-0.82138
-1.14308
1.579793
3.633956
8.672169
0.949866
-1.89536
2.033092
0.846792
2.322305
-2.47517

Top significantly (p<0.05) differentially expressed genes associated with
both IBD and PDAC disease states, as intersected between gut microbiome
and tissue gene expression datasets. There are 27 total genes common to
both illnesses. Genes are ordered according to fold change between healthy
and affected sample groups based on microbiome. LogFC refers to the log
fold change of gene expression.

However, looking at a more low level view of the data, there
were seemingly no similarities between the top differentially
expressed genes between the IBD and PDAC datasets before
merging or comparing. More interestingly, the fold change for
the top up and downregulated samples for the PDAC samples
were much greater than those for the IBD samples, at nearly 6-
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TABLE II
T OP D IFFERENTIALLY E XPRESSED G ENES A SSOCIATED WITH I RRITABLE
B OWEL S YNDROME
Downregulated
C1ORF21
ELOVL6
SLC16A5
KIAA1683
NFIC

Irritable Bowel
Fold Change
-0.76838
-0.68895
-0.65941
-0.58717
-0.5669

Syndrome
Upregulated
GSTT1
SLC19A1
DUSP3
TAPBP
SQSTM1

Fold Change
1.528697
0.890537
0.601571
0.597237
0.591454

Top significantly (p<0.05) differentially expressed genes associated with
both IBD gut microbiome and tissue samples. Genes are ordered according
to fold change between healthy and affected sample groups.
TABLE III
T OP D IFFERENTIALLY E XPRESSED G ENES A SSOCIATED WITH
PANCREATIC D UCT A DENOCARCINOMA
Pancreatic Duct Adenocarcinoma
Downregulated
Fold Change Upregulated Fold Change
S100P
-8.34346
CPA1
13.16132
CEACAM5
-6.99256
CEL
13.08126
MUC5AC
-6.64225
PNLIP
12.16057
CLDN18
-6.61624
CPB1
11.95104
SLC6A14
-5.77941
CELA2B
11.83255
Top significantly (p<0.05) differentially expressed genes associated with
both PDAC pancreatic microbiome and tissue samples. Genes are ordered
according to fold change between healthy and affected sample groups.

20 times their counterparts, as shown by Tables 1 and 2. All of
the top differentially expressed genes are poorly characterized
and have only generalized function such as chromosome
binding or being termed an “intracellular protein”, except
for CPA1 and S100P which showed a high fold change in
PDAC samples (Table 2) [37]–[40]. CPA1 is produced in the
pancreas and preferentially cleaves C-terminal branched-chain
and aromatic amino acids from dietary proteins, thus showing
function in digestive processes [37]. Similarly, S100p is known
to be involved in cellular proliferation of pancreatic cancer as
well as survival and invasion of the tumor [38].
In turn, analyzing these genes using REACTOME and
KEGG also yielded curious results. Processing the IBD dataset
revealed that there were no significantly enriched pathways
associated with the illness, which may be in part to the
limited size of the dataset post-processing. In contrast, with
the PDAC sampleset, the CDC42 GTPase cycle, extracellular
matrix organization, RAC1 GTPase cycle, RHO GTPase cycle,
diseases of signal transduction by growth factor receptors and
second messengers, EPH-Ephrin signaling, synthesis of PC,
RHOB GTPase cycle, and EPHB-mediated forward signaling,
as well as crosslinking of collagen fibrils pathways were all
enriched (Figure 4). All enriched pathways associated with
the PDAC dataset were highly significant, and over half had a
pathway count of over 100. The RHO GTPase cycle was the
most enriched pathway associated with PDAC at a count of
over 225 and p-value of less than 0.004, while the crosslinking
of collagen fibrils pathway was the least enriched with a count
of less than 25 and p-value of approximately 0.016 (Figure 4).
This validates alternative functional annotation of PDAC
and IBD associated pathways via and KEGG diagram
mappings. The KEGG diagram for irritable bowel disease
(hsa05321) only showed two factors that were upregulated: IL-
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Fig. 2. Volcano plot of gene expression, of the most differentially expressed genes (padj <0.05) between IBD-affected and healthy patient samples. Blue
represents significantly downregulated, while red represents significantly upregulated genes. A) Comparison using peripheral blood mononuclear cells [21].
(PBMC). B) Comparison using gut microbiome expression data [23].

Fig. 3. Volcano plot of gene expression, of the most differentially expressed genes (padj <0.05) between healthy patients and patients with pancreatic duct
adenocarcinoma. Blue represents significantly downregulated, while red represents significantly upregulated genes. A) Comparison using healthy and tumorous
tissues [24]. B) Comparison using pancreatic duct biome gene expression [25].
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Fig. 4. REACTOME chart of enriched pathways associated with PDAC: CDC42 GTPase cycle, extracellular matrix organization, RAC1 GTPase cycle, RHO
GTPase cycle, diseases of signal transduction by growth factor receptors and second messengers, EPH-Ephrin signaling, synthesis of PC, RHOB GTPase
cycle, and EPHB-mediated forward signaling, and crosslinking of collagen fibrils pathways. The RHO GTPase cycle is the most enriched pathway at a count
of over 225 and p-value of less than 0.004. Crosslinking of collagen fibrils is one of the least enriched pathways with a count of less than 25 and p-value of
approximately 0.016.

17 and IL-12Rβ1, a component of IL-12 (Figure 5). Accordingly, KEGG indicates that these genes are most involved with
the Th17 cell differentiation pathway as well as with cytokinecytokine receptor interaction. The opposite is seen when
mapping the KEGG pathways for pancreatic cancer, which was
considered synonymous with the KEGG pathway depicting
pancreatic malignancy for the purposes of this experiment
(hsa05212). However, again, we see that more components
are upregulated than downregulated with PDAC. Implicated
genes include RacGEF, Rac, NFκB, PKB/Akt, CASP9, P13K,
Raf, K-Ras, RAI, RAIBP1, PLD1, CDb-12/Rac, JNK, ERK,
EGF, EGFR, Jak1, STAT3, STAT1, mTOR, S6K, p16, CDK4/6,
E2F, p21, GADD45, Bax, POLK, BRCA2, TGFβ, TGFβRI,
SMAD2/3, and SMAD4 (Figure 6). Many of these genes,
such as BRCA2, EGF, Ras, TGFβ, and Bax are well known
genes associated with cellular proliferation, and thus may be
considered putative protooncogenes or associated with pancreatic malignancies. Generally, KEGG indicates genes are most
affiliated with the P13K-Akt signaling pathway, ErbB signaling pathway, Jak-STAT signaling pathway, TGF-βsignaling
pathway, cell cycle, and end products of the p53 signaling
pathway (Figure 6). For both illnesses, KEGG mapping of
genes with a negative fold change indicated that all genes
displayed in both the IBD and PDAC diagrams were minimally
downregulated.
IV. D ISCUSSION
The results elucidate gene and pathway components which
are common to both irritable bowel disorder (IBD) and
pancreatic duct adenocarcinoma (PDAC). Despite implicating
different genes, the illnesses involve similar pathways. For

instance, NFIC and ELOVL6 are common significantly expressed genes between the two illnesses’ microbiomes (Table
1), with ELOVL6 expressed at a fold change of -2.47 and NFIC
a fold change of 2.32 in IBD samples.
ELOVL6 (Elongation Of Long Chain Fatty Acids, member
6) was also the most downregulated common gene between
both illnesses. This gene is known for having an integral
function in catalyzing the first and rate-limiting reaction of the
long-chain fatty acid elongation cycle, as well as a more minor
role in other biological processes such as building membrane
lipids and lipid mediators [41]. Other sources indicate that
ELOV6 is involved in energy metabolism, a mechanism of the
gut, and insulin sensitivity, a responsibility of the pancreas
[42]. Dysfunction of this single gene showed correlation with
insulin resistance. This provides reserved validation of the
initial results that pancreatic and gut dysfunction relating
to ELOVL6 has far reaching implications into the cause of
common gastrointestinal disorders.
In turn, Nuclear Factor 1 C, or NFIC, is a dimeric DNAbinding protein which acts as a transcription or replication
factor for adenovirus [43]. Adenoviruses are a common family of viruses which tend to cause a variety of symptoms,
collectively known as the common cold, although they may
also cause gastrointestinal illnesses [44]. However, to be more
specific, NFIC binds to a palindromic sequence present in viral
and cellular promoters for the replication of these microbes,
so it also has potential function in the replication of specific
bacteria or host cells that display this same primer region.
To this effect, this primer region is found in many animal
and bacterial cells. NFIC also has well characterized function
in gastric tumorigenesis due to its role as a transcriptional
factor [45]. As such, this may allude to NFIC being a genetic
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Fig. 5. KEGG annotation of differentially upregulated genes involved in IBD. KEGG pathway hsa05321 used, referring to illnesses which are implicated in
chronic inflammation of the gastrointestinal tract. These genes are most affiliated with the Th17 cell differentiation pathway as well as with cytokine-cytokine
receptor interaction.
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Fig. 6. KEGG pathway of differentially expressed genes involved in PDAC. KEGG pathway hsa05212 used, referring to infiltrating duct adenocarcinoma, the
most common variety of PDAC. These genes are most affiliated with the P13K-Akt signaling pathway, ErbB signaling pathway, Jak-STAT signaling pathway,
TGF-βsignaling pathway, cell cycle, and end products of the p53 signaling pathway.

component which acts as part of the intersection between
the immune system and microbiome through its pleiotropic
effects.

and energy homeostasis [48]. Such roles are also managed
by the digestive system, and thus malignancies in SLC-family
genes may strongly support disease pathogenesis.

SLC19A1 (Solute Carrier Family 19 [Folate Transporter],
member 1), another common gene, was one of the most
upregulated between both diseases (Table 1). Moreover, pathway analysis revealed that enriched pathways associated with
PDAC primarily work in the GTPase cycle, an important signal
transduction intermediary, or have other signaling functions
(Figure 4). SLC19A1 is also involved in immunostimulatory
signaling and intracellular transport of folate, a vitamin B
complex that is necessary for healthy cell growth [46]. Thus,
mutations in this gene are known to cause a variety of
different cancers, particularly metastatic varieties, including
colorectal cancer [46] and deficiencies in nutrient uptake
[47]. As such, upregulation of this gene may indicate a
corresponding increase in immune signaling, or that IBD and
PDAC have common immune reactions. The solute carrier
family also has critical function in the influx transport of bile
acids, steroidal hormones, various drugs, and several other
substrates, a role which connects this gene group to glucose

CTRL was the most upregulated gene in the discovered gene
set, with a fold change of 8.67 when looking at the PDAC
pancreatic duct microbiome. However, while this can be considered more of a background gene as it has known enzymatic
function in pancreas-associated digestion, it was interestingly
also significantly expressed in irritable bowel syndrome [49].
Consequently, this may validate the aforementioned fact that
the vast majority of IBD cases also present with pancreatic
malignancies [50]. More specifically, mutations in this gene
are known to present with life threatening immune disorders
such as Netherton syndrome which in mild cases presents with
food allergies and inflammatory skin disorders, and in more
severe cases can cause the patient to be more susceptible to
disease by lacking skin protection and sepsis [51]. That is,
CTRL is also implicated in immunodeficiency and thus also
potentially links the gastrointestinal system with the immune
system.
Another gene of interest, CPA1 and S100P, were both
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one of most differentially expressed genes common to both
illnesses, but also the only genes to not simply be termed an
intracellular protein with fairly uncharacterized function. That
is, mutations in CPA1 are known to cause chronic pancreatitis,
while elevated levels of the protein are known to be associated
with pancreatic malignancies including cancer [37]. In turn,
S100P is known to promote pancreatic cancer, as well as
to stimulate cellular proliferation and survival in many other
types of cancer [38]. Thus, these preliminary results validate
that the workflow is correctly identifying the results that we
desire. However, these differences in fold change may also
allude to the adjusted p-value concerns, as a more severe fold
change would likely be more significant than a fold change
that is more minimal.
Pathway analysis also yielded interesting results, as many
of the enriched pathways were involved in GTPase cycling.
Specifically, GTPases are molecular switches or timers in
many fundamental cellular processes, such as signal transduction in response to activation of cell surface receptors [52].
Aberrant signaling of GTPases are known to be connected
with various disorders, such as in the formation of cytoskeletal
barriers which cause inflammation characteristic of IBD [53].
Similarly, from the REACTOME diagram we saw that the
RHO GTPase cycle was the most enriched with an extremely
low p-value of less than 0.004 and count close to 250 (Figure
4). Again, this confirms the findings that we found with the
REACTOME chart for PDAC, that the most enriched pathways are those associated with cell signaling and cytoskeletal
rearrangement, which are hallmarks of cellular proliferation.
Comparing this to the IBD results, we see while the gene
functions involve tissue-based carcinogenesis, there is little
data to implicate the immune system in PDAC pathogenesis.
Conversely, functional annotation of the IBD sample set
yielded minimal results, with only IL-12 and IL-17 being
indicated as the most upregulated components involved in the
illness. Mutations in IL-12 are known to impair the development of interleukin-17-producing T lymphocytes and result
in increased susceptibility to mycobacterial and Salmonella
infections [54], [55]. In turn, IL-17 is a well known proinflammatory cytokine, indicating that upregulation of this gene
may potentially increase gut inflammation, and thus validating
the immune system’s contribution to disease pathogenesis.
The phenomenon of IL-17 overproduction has been shown to
contribute to immunosuppression and nutritional impairment
in patients with gastrointestinal cancers [56].
V. C ONCLUSION
In conclusion, the results provide preliminary evidence that
these common gastrointestinal disorders, irritable bowel disorder (IBD) and pancreatic duct adenocarcinoma (PDAC), have
common etiologies. There are a total of 27 genes common to
both illnesses, expressed by both the bacterial microbiome and
tissue of the patient’s pancreas and gut. Moreover, the illnesses
involve comparable pathways through which malignancies
may putatively lead to similar clinical symptoms. For instance
NFIC and ELOVL6 are common significantly expressed genes
between the two illnesses’ microbiomes (Table 1). ELOVL6 is
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expressed at a fold change of -2.47 and NFIC a fold change
of 2.32 in PDAC samples. ELOVL6 was the most downregulated common gene between both illnesses. SLC19A1,
another common gene, was one of the most upregulated
between both. Each of these genes, ELOVL6, SLC19A1, and
NFIC all have dual functions of being involved in metabolism
as well as immunostimulatory signaling. Moreover, pathway
analysis reveals that enriched pathways associated with PDAC
primarily work in the GTPase cycle, an important signal
transduction intermediary, or have other signaling functions.
Overall, these findings provide substantial evidence which may
support the creation of a diagnostic gene panel for better
clinical distinguishment between IBD and PDAC which are
often underdiagnosed.
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